Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3923-3931

  Alsner, Jan ^a   Overgaard, Jens ^a   Guldberg, Per ^b   Yilmaz, Mette ^a   Hansen, Lise Lotte ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Institute of Cancer Biology   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER SURVIVAL; FEMALE; GENE DISRUPTION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ALLELES; BREAST NEOPLASMS; CODON, NONSENSE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS; EXONS; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENES, P53; HUMANS; MODELS, STATISTICAL; MUTATION; MUTATION, MISSENSE; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY; PHENOTYPE; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033766175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis
2. p53, The cellular gatekeeper for growth and division
3. Structural aspects of the p53 protein in relation to gene evolution: A second look
4. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
5. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
6. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
7. p53 And survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation
8. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor-positive breast cancer patients. Austrian Breast Cancer Study Group
9. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer
10. Determination and use of p53 in the management of cancer patients with special focus on breast cancer: A review
11. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer
12. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement
13. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
14. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR
15. In vitro structure-function analysis of the β-strand 326-333 of human p53
16. p53 Mutants without a functional tetramerisation domain are not oncogenic
17. Sources of bias in the detection and reporting of p53 mutations in human cancer: Analysis of the IARC p53 mutation database
18. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines
19. p53 Mutation as a genetic trait of typical medullary breast carcinoma
20. Gain of function mutations in p53
21. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
22. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
23. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
24. p53 Mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
25. Genetic risk and breast cancer survival: Another link in the chain of evidence
26. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors
27. A cancer family syndrome in twenty-four kindreds
28. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms